The results suggested: compared with the blank control group (shVRK1-NC), shVRK1-1 and shVRK1-2 can significantly knockdown the expression level of VRK1 in bladder cancer cells after transfection, and shVRK1-2 has a higher knockdown efficiency (Figures 2G,H). Here, VRK1 is linked to urinary bladder carcinoma.